Glaxo Diabetes Drug Didn’t Beat Takeda’s Actos in Trial
This article is for subscribers only.
GlaxoSmithKline Plc’s experimental diabetes medicine albiglutide didn’t work better than Takeda Pharmaceutial Co.’s Actos medicine and showed higher rates of gastrointestinal side effects in a study.
Albiglutide didn’t achieve non-inferiority to Actos in a late-stage study dubbed Harmony 5, Glaxo said in a statement today. The results add to evidence from another trial, Harmony 3, where albiglutide lowered blood sugar better than Merck & Co.’s Januvia or Sanofi’s Amaryl, while more patients reported gastrointestinal side effects.